Non-Hodgkin s lymphoma. Univ. Prof. Dr. Werner Linkesch Univ. Klinik Graz
|
|
|
- Avis Terry
- 7 years ago
- Views:
Transcription
1 Non-Hodgkin s lymphoma Univ. Prof. Dr. Werner Linkesch Univ. Klinik Graz NON-HODGKIN S LYMPHOMA (NHL) Approximately 1.5 million people worldwide are living with non-hodgkin s lymphoma (NHL), and it is estimated that 300,000 people die each year from the disease 1 new case diagnosed every 9 minutes* 81% increase in incidence of NHL between NHL is the third fastest growing cancer (excluding the US) in terms of population in the world NHL is leading cause of death due to cancer in men aged years *US statistics 1
2 Proposed WHO Classification of Lymphoid Neoplasms B-Cell neoplasms Precursor B-cell neoplasm: Precursor B-lymphoblastic leukemia/lymphoma (precursor B-ALL) Mature (peripheral) B-cell neoplasms: B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma B-cell prolymphocytic leukemia Lymphoplasmacytic lymphoma Splenic marginal zone B-cell lymphoma (+/- villous lymphocytes) Hairy cell leukemia Plasma cell myeloma/plasmacytoma Extranodal marginal zone B-cell lymphoma of MALT type Nodal marginal zone B-cell lymphoma (+/- monocytoid B cells) Follicular lymphoma Mantle-cell lymphoma Diffuse large B-cell lymphoma Mediastinal large B-cell lymphoma Primary effusion lymphoma Burkitt's lymphoma/burkitt cell leukemia Proposed WHO Classification of Lymphoid Neoplasms T-cell and NK-cell neoplasms Precursor T-cell neoplasm: Precursor T-lymphoblastic lymphoma/leukemia (precursor T-ALL) Mature (peripheral) T-cell neoplasms: T-cell prolymphocytic leukemia T-cell granular lymphocytic leukemia Aggressive NK-cell leukemia Adult T-cell lymphoma/leukemia (HTLV1+) Extranodal NK/T-cell lymphoma, nasal type Enteropathy-type T-cell lymphoma Hepatosplenic gamma-delta T-cell lymphoma Subcutaneous panniculitis-like T-cell lymphoma Mycosis fungoides/sezary syndrome Anaplastic large-cell lymphoma, T/null cell, primary cutaneous type Peripheral T-cell lymphoma, not otherwise characterized Angioimmunoblastic T-cell lymphoma Anaplastic large-cell lymphoma, T/null cell, primary systemic type 2
3 Major NHL Types Category Percentage Incidence Diffuse Large B Cell Follicular Marginal Zone B-Cell, MALT Peripheral T-cell Small B-lymphocytic (CLL) Mantle cell lymphoma Primary mediastinal large B-cell Anaplastic large T/null cell High grade B-cell, Burkitt-like Marginal Zone B-cell, nodal Precursor T-lymphoblastic 31% 22% 8% 7% 7% 6% 2% 2% 2% 2% 2% Indolent Aggressive Highly aggressive Frequency of NHL Subtypes in Adults Composite lymphomas (12%) Small lymphocytic (6%) Follicular (22%) Mantle cell (6%) Peripheral T-cell (6%) Marginal zone B-cell, MALT (5%) Diffuse large B-cell (31%) Other subtypes with a frequency <2% (9%) Marginal zone B-cell, nodal (1%) Lymphoplasmacytic (1%) Armitage et al. J Clin Oncol 1998;16:
4 NHL-Etiology Etiology typically unknown Strong association with long-term immunosuppressive therapy Pathogen: EBV (Burkitt s lymphoma, PTLD) HHV-8 (body cavity, multiple myeloma) Hepatitis C HTLV-1 (Adult T-cell leukemia, lymphoma) Helicobacter pylori (MALT lymphoma) C. jejuni Immunoproliferative small intestinal disease (IPSID) Chlamydie psitacci (ocular adnexal lymphoma) Incidence rate of NHL 4
5 NHL histologic type Translocation % of cases affected Protooncogene involved Mechanism of proto-oncogene activation Proto-oncogene function Lymphoplas macytic lymphoma t(9;14)(p13;q32) 50% PAX-5 Transcriptional deregulation Transcription factor regulating B- cell proliferation and differentiation Follicular lymphoma t(14;18)(q32;q21) t(2;18)(p11;q21) t(18;22)(q21;q11) 90% BCL-2 Transcriptional deregulation Negative regulator of apoptosis Mantle cell lymphoma t(11;14)(q13;q32) 70% BCL-1/ cyclin D1 Transcriptional deregulation Cell cycle regulator MALT lymphoma t(11;18)(q21;q21) t(1;14)(p22;q32) 50% rare API2/MLT BCL-10 Fusion protein Trancriptional deregulation API2 has antiapoptotic activity Anti-apoptosis (?) Diffuse large B-cell lymphoma der(3)(q27) 35% BCL-6 Transcriptional deregulation Transcriptional repressor required for GC formation Burkitt lymphoma t(8;14)(q24;q32) t(2;8)(p11;q24) t(8;22)(q24;q11) 80% 15% 5% c-myc Transcriptional deregulation Transcription factor regulating cell proliferation and growth Anaplastic large T-cell lymphoma t(2;5)(p23;q35) 60%* NPM/ALK Fusion protein ALK is a tyrosine kinase 5
6 The aggressive lymphomas DLCL Peripheral T cell lymphoma Anaplastic large cell lymphomas FL, grade III Mantle cell lymphoma 6
7 Survival Patterns are Different for Indolent and Aggressive NHL Probability of survival (%) Indolent NHL (e.g. Follicular lymphoma) Aggressive NHL (e.g. Diffuse large B-cell lymphoma) Years The Non-Hodgkin s Lymphoma Classification Project. Blood 1997;89:
8 Diffuse large B cell Lymphoma (DLBCL) Most frequent NHL type (31%) Clinics: Usually aggressive Phenotype: Histologic subset and Immunophenotype: CD19+; CD22+; CD10-/+; SIg+ Putative cell of origin: Large transformed B-cells harbouring somatic hypermutation of the Ig genes (ongoing mutations in some cases) Staginguntersuchungen 8
9 Internationaler Prognose-Index Günstig Ungünstig 1. Alter 2. Stadium 3. Zahl der E-Manifestationen 4. Allgemeinzustand ECOG 5. LDH i. S. < 60 Jahre vs. > 60 Jahre I/II vs. III/IV 0; 1 vs. 2 0; 1 vs. 2 normal vs. erhöht INTERNATIONAL PROGNOSTIC INDEX Risk (factors) Distribution CR Five-year DFS Fivefor those in CR survi Low (0-1) Low intermediate (1) High intermediate (2) High (3) 22% 92% 86% 83 32% 78% 66% 69 32% 57% 53% 46 14% 46% 58% 32 9
10 10
11 CHOP DeVita VT Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet 1975 Cyclophosphamide 750 mg/m2 d1 Adriamycine 50mg/ m2 d1 Vincristine 1,4 mg/m2 d1 Prednisone 100mg d1-5 CD20 Expression in B-Cell Development Bone marrow Blood, lymph Pluripote nt stem cell Lymphoid stem cell Pre-B-cell B-cell Activated B-cell CD20 Plasma cell Press. Semin Oncol 1999;265(suppl 14):
12 Rituxan (Rituximab) Chimeric Murine/Human antibody Complement Binds specifically to CD20 antigen on normal and malignant pre-b and mature B lymphocytes CD20 expressed by >90% of B-cell NHL No CD20 on human stem cells, progenitor cells, or normal plasma cells Malignant B Cell Rituximab Lyses lymphocytes via: Antibody dependent cell mediated cytotoxicity Induction of apoptosis CD20 FC Receptor Effector cell GELA LNH-98.5: study design Cyclophosphamide 750mg/m 2 Doxorubicine 50mg/m 2 Vincristine 1.4mg/m 2 Prednisone 40mg/m 2 /d x 5 days 3 weeks 8 cycles CHOP MabThera 375mg/m 2 Patients years old with untreated DLCL Primary endpoint: eventfree survival events: progression, relapse, new alternative treatment, death from any cause Intent-to-treat analysis 399 patients with a median follow-up of 4 years 12
13 13
14 14
15 15
16 MabThera plus ICE (R-ICE) Patients: 45 Second line IPI 1 2: 18 patients CR evaluated with PET scan R-ICE (%) ICE (%) Response rate Complete response Primary refractory CR IPI III/IV (Moskowitz et al. ASH 2001) 16
17 Results of selected studies of pretransplant salvage therapy for aggressive NHL 17
18 18
19 CD20 is an Ideal Target for Radioimmunotherapy CD20 antigen: Proven target for lymphoma therapy Expressed only on B-lineage cells Does not shed into circulation Malignant B-cell CD20 antigen Does not modulate upon antibody Zevalin binding Zelenetz. Curr Opin Oncol 1999;11: Press et al. Blood 1987;69: Wood. Am J Health Sys Pharm 2001;58: Ibritumomab Tiuxetan 90 Y Rationale der Radioimmuntherapie bei NHL NHL sind von Natur aus sehr strahlensensibel Die Radiotherapie kann bei NHL in frühen Stadien kurativ sein Radioaktiv markierte Antikörper bringen die Strahlung zielgerichtet zum Tumor Die Radioimmuntherapie kann sowohl Ziel- als auch Nachbarzellen vernichten ( Kreuzfeuer- Effekt ) und so auch grosse oder gering vaskularisierter Tumoren erreichen 19
20 Die Radioimmuntherapie ermöglicht einen Kreuzfeuer-Effekt Nackter Antikörper Radioaktiv markierter Antikörper Before treatment At 2 cycles FDG-PET ( ) At 4 cycles 20
21 21
Non-Hodgkin s lymphoma
Non-Hodgkin s lymphoma Univ. Prof. Dr. Werner Linkesch Leiter der Klinischen Abteilung für Hämatologie LKH-Univ. Klinikum Graz Univ. Klinik für Innere Medizin NON-HODGKIN S LYMPHOMA (NHL) Approximately
Non-Hodgkin s Lymphoma
Non-Hodgkin s Lymphoma Luis Fayad, MD Assistant Professor Clinical Medical Director Lymphoma/Myeloma Department Non-Hodgkin s Lymphoma Non-Hodgkin s lymphomas (NHL) are a heterogeneous group of malignant
MALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)
MALIGNANT LYMPHOMAS Dr. Olga Vujovic (Updated August 2010) Malignant lymphomas consist of Hodgkin and non-hodgkin lymphomas. The current management of these diseases involves a multi-disciplinary approach.
Lymphoma Diagnosis and Classification
Lymphoma Diagnosis and Classification By Atef Shrit, MD, Pathology B- and T/NK-cell lymphomas are clonal neoplasms of immature and mature B-lymphocytes, T-lymphocytes or natural killer cells at various
Collaboration to collect Autologous transplant outcomes in Lymphoma and Myeloma (CALM) Additional Questionnaire (MED C) INCLUSION CRITERIA CALM STUDY
Additional Questionnaire (MED C) CALM study Inclusion period: 01/01/2008 to 31/12/2011 PATIENT REGISTRATION FORM Disease Diagnosis Lymphoma S Non Hodgkin Lymphoma (NHL) Mature B-cell neoplasm Follicular
What is non-hodgkin lymphoma, how is it treated, and what is the unmet need?
What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? Tim Illidge BSc PhD MRCP FRCR FRCPath Institute of Cancer Sciences, University of Manchester Manchester Cancer Research Centre,
About B Cell Lymphomas Groupmeeting Klipp/Spang, December 09 2002 Dennis Kostka Max-Planck-Institute for Molecular Genetics Computational Molecular Biology Berlin 1 Overview Short History of Lymphoma Classification
LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons
LYMPHOMA BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons Normal development of lymphocytes Lymphocyte proliferation and differentiation:
Lymphoid Neoplasms. Sylvie Freeman Department of Clinical Immunology, University of Birmingham
Lymphoid Neoplasms Sylvie Freeman Department of Clinical Immunology, University of Birmingham Incidence of Haematological Malignancies UK2001 (CRUK) Malignancy New Cases All Cancers 271,000 Leukaemia 6,760
Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data
(Form 2018) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data Form. E-mail comments regarding the content
Mature Lymphoproliferative disorders (2): Mature B-cell Neoplasms. Dr. Douaa Mohammed Sayed
Mature Lymphoproliferative disorders (2): Mature B-cell Neoplasms Dr. Douaa Mohammed Sayed Small lymphocytic lymphoma/b-cell chronic lymphocytic leukemia BMB: nodular, interstitial, diffuse or a combination
Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)
Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade
CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY
CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY 26.1 Introduction rituximab Subsequent to the completion of drafts for the guidelines earlier in 2004,
Aggressive lymphomas. Michael Crump Princess Margaret Hospital
Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:
A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on
A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on examination. She also has fever, weight loss, and sweats. What
Mantle Cell Lymphoma Understanding Your Treatment Options
New Developments in Mantle Cell Lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department
Frequency of NHL Subtypes in Adults
Chemotherapy Options Stephanie A. Gregory, M.D. The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Frequency of NHL Subtypes in Adults
Malignant Lymphomas and Plasma Cell Myeloma
Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations
Diffuse Large B-cell Lymphoma, Burkitt Lymphoma and the Gray Zone. Relative Frequency of B-cell NHL. Diffuse Large B-cell Lymphoma Definition
Diffuse Large B-cell Lymphoma, Burkitt Lymphoma and the Gray Zone L. Jeffrey Medeiros, M.D. M.D. Anderson Cancer Center Relative Frequency of B-cell NHL Diffuse large B-cell lymphoma 37 % Follicular lymphoma
Rituximab in Non - Hodgkins Lymphoma. Fatima Bassa, Dept. of Haematology October 2008
Rituximab in Non - Hodgkins Lymphoma Fatima Bassa, Dept. of Haematology October 2008 World Health Organization lymphoma classification (2001) Peripheral B-cell neoplasms: B-chronic lymphocytic leukemia/small
FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma
Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable
6/3/2013. Follicular and Other Slow Growing Lymphomas. Stephen Ansell, MD, PhD Mayo Clinic
Follicular and Other Slow Growing Lymphomas Stephen Ansell, MD, PhD Mayo Clinic 1 Learning Objectives Start with an overview of Follicular and other slow growing lymphomas Discuss current and emerging
Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?
Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in
Indolent Lymphomas. American Academy of Insurance Medicine 121 st Annual Meeting. Hilton LaJolla October 2012
Indolent Lymphomas American Academy of Insurance Medicine 121 st Annual Meeting Hilton LaJolla October 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC,
B-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
2008 WHO Classification of Lymphoid Neoplasms: Small B-Cell Neoplasms Chronic lymphocytic leukemia/small lymphocytic lymphoma B-cell prolymphocytic leukemia Splenic marginal zone B-cell lymphoma Hairy
Audience Response Question?
Presenter Disclosure Information Session 4: 3:30 PM - 4:15 PM Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management Speaker: Arnold S. Freedman, MD The following relationships
Audience Response Question? Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management. Presenter Disclosure Information
Welcome to Master Class for Oncologists Session 4: 10:00 AM - 10:45 AM Miami, FL December 18, 2009 Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management Speaker: Arnold S. Freedman,
Oncology Best Practice Documentation
Oncology Best Practice Documentation Click on the desired Diagnoses link or press Enter to view all information. Diagnoses: Solid Tumors Lymphomas Leukemias Myelodysplastic Syndrome Pathology Findings
Medical Policy Manual. Topic: Hematopoietic Stem-Cell Transplantation for Non- Hodgkin Lymphomas. Date of Origin: May 2010
Medical Policy Manual Topic: Hematopoietic Stem-Cell Transplantation for Non- Hodgkin Lymphomas Date of Origin: May 2010 Section: Transplant Last Reviewed Date: August 2015 Policy No: 45.23 Effective Date:
Update on Follicular Lymphoma. Brad Kahl, M.D.
Update on Follicular Lymphoma Brad Kahl, M.D. Follicular Lymphoma: 25% of NHL Cases Other subtypes (9%) T and NK cell (12%) Burkitt (2.5%) Diffuse large B cell (DLBCL) (30%) Mantle cell (6%) Follicular
Non-Hodgkin Lymphoma Richard Orlowski, MD
Non-Hodgkin Lymphoma Richard Orlowski, MD The American Cancer Society (ACS) estimates that 69,740 Americans will be diagnosed with non-hodgkin lymphoma (NHL) in 2013. Excluding non-melanoma skin cancers,
Anti-HCV therapy in HCV-related NHL
Gabriele Pozzato M.D. University of Trieste Anti-HCV therapy in HCV-related NHL Questions about HCV+ in NHL Is the NHL related with HCV infection? Which is the best therapeutic strategy? Is the antiviral
Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma
a report by Martin Dreyling Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma Head, Lymphoma Section, Department of Medicine III, University Hospital Großhadern, Ludwig Maximilians-University
Non-Hodgkin Lymphoma in Queensland An Overview 2012
Non-Hodgkin Lymphoma in Queensland An Overview 2012 Acknowledgements The authors acknowledge and appreciate the work of Queensland Health staff that contribute to and participate in the maintenance of
David Loew, LCL MabThera
MabThera The star continues to rise David Loew, LCL MabThera MabThera the star continues to raise Group sales (CHF bn) 4,5 4,0 3,5 3,0 2,5 2,0 1,5 1,0 0,5 0,0 2001 2002 2003 2004 2005 Outstanding clinical
Immunohistochemical classification of malignant lymphomas
Immunohistochemical classification of malignant lymphomas Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark Thanks to Jan Klos Important issues Distinction from non-hematopoietic neoplasms
New Targets and Treatments for Follicular Lymphoma. Disclosures
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Disclosures Consulting fees from:
Histopathologic results
Self evaluation 1 Clinical Case 55-year-old woman Bilateral enlargement of cervical, axillary and inguinal lymph nodes, largest diameter > 6 cm Hepatosplenomegaly. Enlargement of retroperitoneal, mesenteric
Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma Bendamustine with rituximab for the first-line
亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引
前 言 : 惡 性 淋 巴 瘤 ( 或 簡 稱 淋 巴 癌 ) 乃 由 體 內 淋 巴 系 統 包 括 淋 巴 細 胞 淋 巴 管 淋 巴 腺 及 一 些 淋 巴 器 官 或 組 織 如 脾 臟 胸 腺 及 扁 桃 腺 等 所 長 出 的 惡 性 腫 瘤 依 腫 瘤 病 理 組 織 型 態 的 不 同 可 分 為 何 杰 金 氏 淋 巴 瘤 (Hodgkin s disease) 與 非 何 杰 金
Perspectives on Recent Non-Hodgkin s Lymphoma (NHL) Data
Perspectives on Recent Non-Hodgkin s Lymphoma (NHL) Data Summary Article James O. Armitage, MD Presented through a strategic collaboration by A series of 5 expert interviews were conducted, focusing on
Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014
ABOUT BLOOD CANCERS Leukemia, Hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the
Effective for dates of service on or after September 1, 2015, refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm
Effective for dates of service on or after September 1, 2015, refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm Name of Policy: Uses of Monoclonal Antibodies for the Treatment of Non-Hodgkin
Understanding Non-Hodgkin Lymphoma
Understanding Non-Hodgkin Lymphoma A Guide For Patients, Survivors, and Loved Ones Fourth Edition This guide is an educational resource compiled by the Lymphoma Research Foundation (LRF) that provides
Lymphoma: An Overview. Dr Louise Connell 05/03/2103
Lymphoma: An Overview Dr Louise Connell 05/03/2103 Overview Concepts, classification, biology Epidemiology Clinical presentation Diagnosis/Staging Treatment/Prognosis Stem cell transplantation What is
Leukemias and Lymphomas: A primer
Leukemias and Lymphomas: A primer Normal blood contains circulating white blood cells, red blood cells and platelets 700 red cells (oxygen) 1 white cell Neutrophils (60%) bacterial infection Lymphocytes
Two Retroperitoneal Low-Grade B-Cell Lymphoma Successfully Treated With a Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy
Two Retroperitoneal Low-Grade B-Cell Lymphoma Successfully Treated With a Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy Yoichi Kitamura, MD Kazuhiko Hayashi, MD Kazumi Uchida,
CAR T cell therapy for lymphomas
CAR T cell therapy for lymphomas Sattva S. Neelapu, MD Associate Professor and Deputy Chair ad interim Department of Lymphoma and Myeloma UT MD Anderson Cancer Center, Houston, TX CAR T cell therapy What
Flow Cytometric Evaluation of B-cell Lymphoid Neoplasms
Clin Lab Med 27 (2007) 487 512 Flow Cytometric Evaluation of B-cell Lymphoid Neoplasms Fiona E. Craig, MD Division of Hematopathology, Department of Pathology, University of Pittsburgh School of Medicine,
Follicular Lymphoma. Aruna K. Reddy, MD. Hematology& Oncology Peace Health Southwest Medical Center
Follicular Lymphoma Aruna K. Reddy, MD Hematology& Oncology Peace Health Southwest Medical Center Follicular Lymphoma Malignant neoplasm resulting from clonal proliferation of malignant B-cells Second
Non Hodgkin Lymphoma:
Non Hodgkin Lymphoma: Non Hodgkin Lymphoma, often referred to as NHL, is a cancer originating in the lymphocytes, a type of blood cell, which are integral to the body s immune system. Non Hodgkin Lymphoma
Chronic lymphocytic EBMT Slideleukemia. University of Heidelberg, Germany March 22, 2010. The European Group for Blood and Marrow Transplantation
Chronic lymphocytic EBMT Slideleukemia template Peter Barcelona Dreger Chairman, CLL 7 February subcommittee 2008 University of Heidelberg, Germany March 22, 2010 The European Group for Blood and Marrow
Interesting Case Review. Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA
Interesting Case Review Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA History 63 y/o male with h/o CLL for 10 years Presents with worsening renal function and hypercalcemia
Michael Crump MD. Lymphoma Site Leader Princess Margaret Hospital University of Toronto
Evolution of Lymphoma Therapy: What can we expect for the rest of the millenium decade? Michael Crump MD Lymphoma Site Leader Princess Margaret Hospital University of Toronto disclaimers Served on advisory
Non-Hodgkin s Lymphoma
LYMPHOMA Non-Hodgkin s Lymphoma About 71,380 people living in the United States will be diagnosed with lymphoma in 2007. This figure includes approximately 8,190 new cases of Hodgkin lymphoma (4,470 males
Rituximab in non-hodgkin Lymphoma (NHL)
Original Article ISSN: 2070-254X Rituximab in non-hodgkin Lymphoma (NHL) Manal Elhabbash MD 1, Abukris Alwindi MD 2 (1) Assistant Professor, Tripoli University, (2) Medical consultant in oncology & hematology
Lymphoproliferative Disorders
Lymphoproliferative Disorders Learning outcomes Lymphocyte Ontogeny: know types and origin of lymphocytes Function of lymphocytes Lyphoprloifertive Disorders Acute vs Chronic Principles of diagnosis Definition
Guidelines for the Management of Follicular Lymphoma
Guidelines for the Management of Follicular Lymphoma Scope The following guidance for first- and second-line therapy applies to follicular lymphoma histological grades 1, 2 and 3a according to the World
Non-Hodgkin s lymphomas (NHLs) are a
Oncology 33 Non-Hodgkin s lymphoma in the elderly The incidence of non-hodgkin s lymphoma (NHL) is increasing, and this increase is even more rapid in the older population. Although treatment of NHL in
Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics
Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics Disclosure(s) I do not intend to discuss an off-label use
DIFFUSE LARGE B-CELL LYMPHOMA
DIFFUSE LARGE B-CELL LYMPHOMA Executive Summary Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-hodgkin lymphoma (NHL), constituting up to 40% of all cases globally.[1] This subtype
Non-Hodgkin Lymphoma. Rick, non-hodgkin lymphoma survivor
Non-Hodgkin Lymphoma Rick, non-hodgkin lymphoma survivor This publication was supported in part by grants from Revised 2013 A Message From John Walter President and CEO of The Leukemia & Lymphoma Society
MULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist
MULTIPLE MYELOMA Dr Malkit S Riyat MBChB, FRCPath(UK) Consultant Haematologist Multiple myeloma is an incurable malignancy that arises from postgerminal centre, somatically hypermutated B cells.
Because non-hodgkin's lymphoma is a more frequent and distinct disease I will discuss it in more details in this site study.
Southern New Hampshire Medical Center Site report 2009 Lymphomas. Roger Hakimian, MD Foundation Hematology/Oncology 10 Prospect Street, Suite 202 Introduction Lymphomas are group of heterogeneous malignancy
EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
perc also deliberated on the alignment of bendamustine with patient values. perc noted that bendamustine has a progression-free survival advantage, may be less toxic than currently available therapies
The use of monoclonal antibodies in the setting of HSCT
The use of monoclonal antibodies in the setting of HSCT S Montoto, Barts Cancer Institute, London, UK Geneva 3/April/2012 www.ebmt.org Some definitions of interest: Ab and Ag Antibody (Ab)=Immunoglobulin
Guidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre
Guidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre Background Non-Hodgkin s lymphoma (NHL) makes up approximately 85% of all lymphomas. They are a heterogeneous collection
Lymphoma Overview Joseph Leach, MD
Lymphoma Overview Joseph Leach, MD 71 year old male presents with complaints of mild fa5gue and a visible mass in the le: supraclavicular region PE demonstrates a firm easily palpable mass in the le: supraclavicular
An estimated 55,000 to 60,000 new cases of non- Non-Hodgkin Lymphoma: Diagnosis and Treatment STEPHEN M. ANSELL, MD, PHD, AND JAMES ARMITAGE, MD
SYMPOSIUM ON ONCOLOGY PRACTICE: HEMATOLOGICAL NON-HODGKIN LYMPHOMA: DIAGNOSIS MALIGNANCIES AND TREATMENT Non-Hodgkin Lymphoma: Diagnosis and Treatment STEPHEN M. ANSELL, MD, PHD, AND JAMES ARMITAGE, MD
PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA
2012 1 31,, PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA Version 1.0 2012 DIVISION OF HAEMATOLOGY / ONCOLOGY DEPARTMENT OF MEDICINE KAOHSING VETERAN GENERAL HOSPTIAL General Guide Diagnosis 1.Adequate
Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
www.e-mercy.com Mercy Health Fairfield Hospital Annual Report on 2010 Activities Non-Hodgkin Lymphoma Outcomes Study
www.e-mercy.com Mercy Health Fairfield Hospital Annual Report on 2010 Activities Non-Hodgkin Lymphoma Outcomes Study Cancer Program Summary The Cancer Program at Mercy Health - Fairfield Hospital has maintained
Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma What is non-hodgkin lymphoma? Cancer starts when cells in the body begin to grow out of control. Cells in nearly any part of the body can become cancer, and can spread to other areas
Lymphoplasmacytic Lymphoma. Hematology fellows conference 4/12/2013 Christina Fitzmaurice, MD, MPH
Lymphoplasmacytic Lymphoma versus IGM Multiple Myeloma Hematology fellows conference 4/12/2013 Christina Fitzmaurice, MD, MPH Hematology consult patient 48 yo woman presents to ER with nonspecific complaints:
Outline of thesis and future perspectives.
Outline of thesis and future perspectives. This thesis is divided into two different sections. The B- section involves reviews and studies on B- cell non- Hodgkin lymphoma [NHL] and radioimmunotherapy
Hematopoietic Stem Cell Transplantation for Non- Hodgkin Lymphomas
Hematopoietic Stem Cell Transplantation for Non- Hodgkin (80120) Medical Benefit Effective Date: 04/01/13 Next Review Date: 05/16 Preauthorization Yes Review Dates: 04/07, 05/08, 05/09, 05/10, 05/11, 05/12,
Peripheral T-Cell Lymphoma Facts
Peripheral T-Cell Lymphoma Facts No. 25 in a series providing the latest information for patients, caregivers and healthcare professionals www.lls.org Information Specialist: 800.955.4572 Highlights l
Update in Hematology Oncology Targeted Therapies. Mark Holguin
Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning
Updating the 2008 WHO Classification of Small B cell lymphomas Elias Campo
Updating the 2008 WHO Classification of Small B cell lymphomas Elias Campo Hospital Clinic, University of Barcelona Barcelona, Spain Disclosure of Relevant Financial Relationships Dr. ELIAS CAMPO declares
Indolent Lymphomas. Dr Ram Malladi
Indolent Lymphomas Dr Ram Malladi Follicular lymphoma is commonest indolent lymphoma INDOLENT LYMPHOMA % of all NHL Follicular Lymphoma 22 Small lymphocytic lymphoma 6 Marginal zone lymphoma 6 Lymphoplasmacytic
Treatment of low-grade non-hodgkin lymphoma
Produced 28.02.2011 Due for revision 28.02.2013 Treatment of low-grade non-hodgkin lymphoma Lymphomas are described as low grade if the cells appear to be dividing slowly. There are several kinds of low-grade
Interesting Case Series. Periorbital Richter Syndrome
Interesting Case Series Periorbital Richter Syndrome MarkGorman,MRCS,MSc, a Julia Ruston, MRCS, b and Sarath Vennam, BMBS a a Division of Plastic Surgery, Royal Devon and Exeter Hospital, Exeter, Devon,
Diffuse large B-cell lymphoma: the curable disease?
Hematology Meeting Reports 2007; 1(5):77 86 Diffuse large B-cell lymphoma: the curable disease? Michael Pfreundschuh Med Klinik I, Saarland University Medical School, Homburg/Saar, Germany Corresponding
Cancer. 9p21.3 deletion. t(12;21) t(15;17)
CANCER FISH PROBES INDIVIDUAL AND PANEL S Acute Lymphoblastic Leukemia (ALL) ALL FISH Panel (includes all probes below) 8010 LSI MYB/CEP6 LSI p16 (CDKN2A) LSI BCR/ABL with ASS LSI ETV6 (TEL)/AML1 (RUNX1)
Corporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
Lymphoma. Measurability of Quality Performance Indicators Version 2.0
Lymphoma Measurability of Quality Performance Indicators Version 2.0 To be read in conjunction with: Lymphoma Clinical Quality Performance Indicators (September 2013) Lymphoma Data Definitions V2.0 (September
Why discuss CLL? Common: 40% of US leukaemia. approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time
Why discuss CLL? Common: 40% of US leukaemia approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time Median age of dx is 65 (30s. Incurable, survival 2-202 20 years Require ongoing supportive care
Low grade non-hodgkin Lymphoma
Low grade non-hodgkin Lymphoma www.lymphomas.org.uk The knowledge to challenge lymphatic cancers The Lymphoma Association provides: freephone helpline emotional support for those affected by lymphomas
Severe rheumatoid arthritis (a disease that causes inflammation of the joints),where MabThera is given intravenously together with methotrexate.
EMA/614203/2010 EMEA/H/C/000165 EPAR summary for the public rituximab This is a summary of the European public assessment report (EPAR) for. It explains how the Committee for Medicinal Products for Human
J Clin Oncol 23:8447-8452. 2005 by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 33 NOVEMBER 20 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma Richard I. Fisher, Michael
Chemoimmunotherapy resistant follicular lymphoma A single institutional study
Cancer Research Journal 2014; 2(5): 93-97 Published online September 30, 2014 (http://www.sciencepublishinggroup.com/j/crj) doi: 10.11648/j.crj.20140205.13 ISSN: 2330-8192 (Print); ISSN: 2330-8214 (Online)
Many people with non-hodgkin lymphoma have found an educational support group helpful. Support
Track 2: Treatment Options [Narrator] Many people with non-hodgkin lymphoma have found an educational support group helpful. Support groups take many forms: some meet the needs of people with all kinds
In the last decade, passive immunotherapy
Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Immunotherapy with Rituximab in Follicular Lymphomas Carmen SAGUNA, MD a ; Ileana Delia MUT, MD, PhD a ; Anca Roxana LUPU, MD, PhD a ; Mihaela TEVET,
CLL: Disease Course, Treatment, Diagnosis, and Biomarkers
CLL: Disease Course, Treatment, Diagnosis, and Biomarkers Amy E. Hanlon Newell, Ph.D. Manager, Scientific Affairs Abbott Molecular Overview: Today s Take-away Understanding of: Cell phenotype and clinical
Subclassifying DLBCL. Diffuse Large B-Cell Lymphoma: Variants & Subtypes. Subclassifying DLBCL
Diffuse Large B-Cell Lymphoma: Variants & Subtypes Patrick Treseler, MD, PhD University of California San Francisco Subclassifying DLBCL An Entity in Search of a Meaningful Classification Subclassifying
IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN
+ IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN Rena Buckstein MD FRCPC Head Hematology Site Group Sunnybrook Odette Cancer Center (OCC) Head of Hematology Clinical Trials Group at OCC + Outline Start
Lymphomas after organ transplantation
Produced 21.03.2011 Revision due 21.03.2011 Lymphomas after organ transplantation People who have undergone an organ transplant are more at risk of developing lymphoma known as post-transplant lymphoproliferative
Treatment and Care of Cancer Patients: Colorectal Cancer, Pancreatic Cancer, Lymphoma, and Bone Metastasis
Treatment and Care of Cancer Patients: Colorectal Cancer, Pancreatic Cancer, Lymphoma, and Bone Metastasis Satellite Conference and Live Webcast Friday, May 10, 2013 8:30 10:30 a.m. Central Time Produced
Your NHL Journey. RITUXAN for Follicular Lymphoma and Diffuse Large B-cell Lymphoma (DLBCL) Indications. Important Safety Information
* Your NHL Journey RITUXAN for Follicular Lymphoma and Diffuse Large B-cell Lymphoma (DLBCL) * Non-Hodgkin s Lymphoma Indications RITUXAN (rituximab) is indicated for the treatment of: Follicular CD20-positive
EU Media Inquiries: Satu Kaarina Glawe Phone: +49 (0) 2638 947 9218 Mobile: +49 (172) 294 6264 Email: sglawe@its.jnj.com
EU Media Inquiries: Satu Kaarina Glawe Phone: +49 (0) 2638 947 9218 Mobile: +49 (172) 294 6264 Email: sglawe@its.jnj.com Investor Relations: Stan Panasewicz Phone: +1 732-524-2524 Louise Mehrotra Phone: